Neurocrine Biosciences (NBIX) Long-Term Investments (2010 - 2026)

Neurocrine Biosciences has reported Long-Term Investments for 17 years, with the latest figure at $147.3 million in Q2 2026.

• Long-Term Investments for Q2 2026 came in at $147.3 million, down 83.14% year-over-year; the trailing twelve-month figure through Jun 2026 was $147.3 million (down 83.14% YoY), and the FY2025 annual result was $1.1 billion, up 43.75% from the prior year.
• Long-Term Investments slipped to $147.3 million in Q2 2026, from $1.3 billion in the prior quarter.
• Over five years, Long-Term Investments peaked at $1.3 billion in Q1 2026 and troughed at $147.3 million in Q2 2026.
• A 5-year average of $627.1 million and a median of $640.8 million in 2024 frame the typical range for Long-Term Investments.
• The widest annual swing landed in 2024, when Long-Term Investments surged 186.35%; it then tumbled 83.14% in 2026.
• A 5-year view of Long-Term Investments shows it stood at $299.4 million in 2022, then soared by 129.63% to $687.5 million in 2023, then grew by 7.56% to $739.5 million in 2024, then soared by 43.75% to $1.1 billion in 2025, then plunged by 86.14% to $147.3 million in 2026.
• Per Business Quant data, the three most recent Long-Term Investments figures were $147.3 million in Q2 2026, $1.3 billion in Q1 2026, and $1.1 billion in Q4 2025.